[关键词]
[摘要]
年龄相关性黄斑变性(age-related macular degeneration,AMD)是目前老年人的主要致盲因素。近90%AMD患者的严重视力丧失是由脉络膜新生血管(choroidal neovascularization,CNV)所引起。维替泊芬(verteporfin)是目前唯一被批准用于光动力疗法(photodynamic therapy,PDT)治疗新生血管性AMD的光敏剂。本文综述了近年来维替泊芬和抗血管生成药物联合治疗新生血管性AMD的新进展,并探讨其治疗效果的差异和视力恢复情况。
[Key word]
[Abstract]
·Age-related macular degeneration(AMD)is the major reason for blindness of elder people in the world.Choroidal neovascularization(CNV)accounts for approximately 90% of severe vision loss caused by AMD.Verteporfin is the only photosensitiser in clinical application of photodynamic therapy(PDT)for treatment of AMD induced by CNV.This paper will give an overview on recent advances of combination therapy with verteporfin and antiangiogenic drugs for treatment of AMD induced by CNV,followed by investigating the difference efficacy of the treatment and the recovery of the eyesight.
[中图分类号]
R774.5
[基金项目]
中国国家自然科学基金资助项目（No.30371737）
